{"id":"https://openalex.org/W2279515414","doi":"https://doi.org/10.1200/jco.2010.28.15_suppl.7614","title":"Serum VEGF and COX-2/5LOX inhibition in advanced non-small cell lung cancer: Cancer and Leukemia Group B 150304.","display_name":"Serum VEGF and COX-2/5LOX inhibition in advanced non-small cell lung cancer: Cancer and Leukemia Group B 150304.","publication_year":2010,"publication_date":"2010-05-20","ids":{"openalex":"https://openalex.org/W2279515414","doi":"https://doi.org/10.1200/jco.2010.28.15_suppl.7614","mag":"2279515414"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2010.28.15_suppl.7614","doi":"https://doi.org/10.1200/jco.2010.28.15_suppl.7614","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2010.28.15_suppl.7614","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5063441489","display_name":"Martin Joseph Edelman","orcid":"https://orcid.org/0000-0002-3752-0726","observed_orcids":["https://orcid.org/0000-0002-3752-0726"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"M. J. Edelman","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110096364","display_name":"Lydia C. Hodgson","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"L. Hodgson","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075091633","display_name":"X. F. Wang","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"X. F. Wang","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029186856","display_name":"Robert H. Christenson","orcid":"https://orcid.org/0000-0003-2612-9083","observed_orcids":["https://orcid.org/0000-0003-2612-9083"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"R. Christenson","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063904421","display_name":"Everett E. Vokes","orcid":"https://orcid.org/0000-0002-8645-8068","observed_orcids":["https://orcid.org/0000-0002-8645-8068"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"E. E. Vokes","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5008573977","display_name":"Robert Arthur Kratzke","orcid":"https://orcid.org/0000-0002-1599-7494","observed_orcids":["https://orcid.org/0000-0002-1599-7494"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"R. A. Kratzke","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"28","issue":"15_suppl","first_page":"7614","last_page":"7614"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10678","display_name":"Inflammatory mediators and NSAID effects","score":0.7554000020027161,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10678","display_name":"Inflammatory mediators and NSAID effects","score":0.7554000020027161,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10422","display_name":"Angiogenesis and VEGF in Cancer","score":0.16269999742507935,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12334","display_name":"Lung Cancer Research Studies","score":0.017000000923871994,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/non-small-cell-lung-cancer","display_name":"non-small cell lung cancer","score":0.9319999814033508},{"id":"https://openalex.org/keywords/cox-2-inhibition","display_name":"COX-2 inhibition","score":0.8809999823570251},{"id":"https://openalex.org/keywords/5-lipoxygenase-inhibition","display_name":"5-lipoxygenase inhibition","score":0.9829999804496765},{"id":"https://openalex.org/keywords/eicosanoids","display_name":"eicosanoids","score":0.9079999923706055},{"id":"https://openalex.org/keywords/prostaglandin-e2","display_name":"prostaglandin E2","score":0.8799999952316284},{"id":"https://openalex.org/keywords/5-hydroxyeicosatetraenoic-acid","display_name":"5-hydroxyeicosatetraenoic acid","score":0.9340000152587891},{"id":"https://openalex.org/keywords/prognostic-factors","display_name":"prognostic factors","score":0.9539999961853027},{"id":"https://openalex.org/keywords/survival","display_name":"survival","score":0.5740000009536743},{"id":"https://openalex.org/keywords/cox-2-expression","display_name":"COX-2 expression","score":0.7770000100135803}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8912338018417358},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.6483269929885864},{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.6295797824859619},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.5805060267448425},{"id":"https://openalex.org/C167734588","wikidata":"https://www.wikidata.org/wiki/Q4356503","display_name":"VEGF receptors","level":2,"score":0.5497633814811707},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.47439125180244446},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4652954339981079},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.4547027051448822}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2010.28.15_suppl.7614","doi":"https://doi.org/10.1200/jco.2010.28.15_suppl.7614","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2010.28.15_suppl.7614","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2017976137","https://openalex.org/W2601822771","https://openalex.org/W2055323688","https://openalex.org/W2376374308","https://openalex.org/W2370153690","https://openalex.org/W2385312177","https://openalex.org/W2375231221","https://openalex.org/W2027329085","https://openalex.org/W2017642498","https://openalex.org/W2360733856"],"abstract_inverted_index":{"7614":[0],"Background:":[1],"Eicosanoids,":[2],"including":[3],"PGE-2":[4,25],"and":[5,26,56,93,110,143],"5-HETE,":[6,27],"can":[7],"increase":[8],"blood":[9,156],"levels":[10,23,30,87,123,179,197,217,264],"of":[11,18,24,31,71,104],"vascular":[12],"endothelial":[13],"growth":[14],"factor":[15],"(VEGF).":[16],"Overexpression":[17],"COX-2":[19,98,105,144,224,239,271,278],"or":[20,90,106,240],"5-LOX":[21,137,235,241,280],"increases":[22],"respectively.":[28],"Elevated":[29],"VEGF":[32,47,122,168,178,196,216,255,263],"are":[33,265],"common":[34],"in":[35,48,54,74,78,118,163,208,261],"patients":[36,52,79,116,154],"with":[37,80,97,155,185,222,234,238,268],"non-":[38],"small":[39],"cell":[40],"lung":[41],"cancer":[42],"(NSCLC).":[43],"We":[44],"prospectively":[45],"measured":[46],"serum":[49,112,177,254],"collected":[50,114],"from":[51,115,158],"enrolled":[53,117],"Cancer":[55],"Leukemia":[57],"Group":[58],"B":[59],"30203":[60,160],"(J":[61],"Clin":[62],"Oncol,":[63],"26:848-55,":[64],"2008),":[65],"a":[66,199,209,257],"randomized":[67],"phase":[68],"II":[69],"study":[70],"eicosanoid":[72],"modulation":[73],"addition":[75],"to":[76,83,102,277,288],"chemotherapy":[77],"advanced":[81],"NSCLC,":[82],"determine":[84],"whether":[85,94],"these":[86],"had":[88],"prognostic":[89,259],"predictive":[91],"significance":[92],"they":[95,275],"correlated":[96,184,221,267],"expression":[99,225],"and/or":[100,279],"responded":[101],"inhibition":[103,281],"5-LOX.":[107],"Methods:":[108],"Pre":[109],"post-treatment":[111],"was":[113,134,170],"CALGB":[119,159],"30203.":[120],"Serum":[121],"were":[124,161,218],"determined":[125],"using":[126],"ELISA":[127],"(R&D":[128],"Systems).":[129],"Pretreatment":[130],"formalin":[131],"fixed":[132],"tissue":[133],"stained":[135],"for":[136,214],"(clone":[138,145],"33,":[139],"BD":[140],"Transduction":[141],"Labs)":[142],"SP21,":[146],"LabVision":[147],"Corp)":[148],"by":[149],"immunohistochemistry.":[150],"Results:":[151],"Eighty":[152],"eight":[153],"specimens":[157],"included":[162],"analysis.":[164],"The":[165],"median":[166,182],"baseline":[167,223,269],"level":[169],"502":[171],"pg/mL":[172],"(range":[173],"55-3453":[174],"pg/ml).":[175],"Dichotomized":[176],"at":[180],"the":[181,246],"inversely":[183],"survival":[186],"time":[187],"(log":[188],"rank":[189],"test,":[190,204],"p":[191,205,230],"=":[192,206,228,231],"0.008),":[193],"as":[194,198],"did":[195,243],"continuous":[200],"explanatory":[201],"variable":[202,260],"(Wald":[203],"0.042)":[207],"Cox":[210],"regression":[211],"model":[212],"adjusting":[213],"age.":[215],"not":[219,244,266],"significantly":[220],"(Pearson":[226],"r":[227],"0.1127,":[229],"0.417),":[232],"nor":[233,273],"expression.":[236],"Treatment":[237],"inhibitors":[242],"alter":[245],"levels.":[247],"Conclusions:":[248],"These":[249],"data":[250],"indicate":[251],"that":[252],"elevated":[253],"is":[256],"negative":[258],"NSCLC.":[262],"tumor":[270],"expression,":[272],"do":[274],"respond":[276],"plus":[282],"chemotherapy.":[283],"No":[284],"significant":[285],"financial":[286],"relationships":[287],"disclose.":[289]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}